Want to see GB:AGY full AI Analyst Report?
AGY Stock Chart & Stats
11.80 p
-0.04 p(-0.55%)
At close: 4:00 PM EST
11.80 p
-0.04 p(-0.55%)
Day’s Range― - ―
52-Week Range5.68 p - 12.10 p
Previous CloseN/A
Volume22.64K
Average Volume (3M)460.33K
Market Cap
£411.61M
Enterprise Value591.39 p
Total Cash (Recent Filing)£10.08M
Total Debt (Recent Filing)£26.75M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Sep 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£258.60M
Bulls Say, Bears Say
Bulls Say
Vertical IntegrationOwning development, manufacturing and commercialization gives lasting control over product quality, regulatory compliance and supply continuity in regulated European markets. This vertical structure supports margin resilience and faster product iteration versus pure-play distributors.
Focused AIT Product PortfolioA concentrated portfolio in allergen immunotherapy targets chronic conditions with recurring treatment cycles and established clinical demand. Structural patient need and specialist prescribing for respiratory allergies underpin more predictable long-term revenue streams than one-off therapeutics.
Specialist Distribution ChannelsUse of national distributors plus named‑patient/specialist prescription routes creates higher barriers to entry and deeper clinician relationships. These channels support durable market access, reimbursement navigation and stickier customer relationships versus OTC or broad retail channels.
Bears Say
Stressed Balance SheetNegative equity and elevated leverage materially limit financial flexibility. Over the medium term this raises refinancing risk, constrains R&D and commercial investment, and increases vulnerability to adverse reimbursement or regulatory shifts that require capital to manage.
Negative Operating And Free Cash FlowSustained cash burn erodes runway and forces reliance on external funding. This undermines the company’s ability to scale commercial launches, invest in manufacturing capacity or pursue clinical programs without dilutive financing, impairing long-term strategic optionality.
Declining Revenue And Heavy LossesMaterial top-line contraction and severe margin erosion indicate structural demand or commercialization issues. Persistent losses reduce ability to self-fund recovery, complicate partnerships, and may force cost cuts that impair growth, making operational turnaround challenging.
Allergy Therapeutics News
AGY FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest share price was 5.67 p and its highest was 12.10 p in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is £411.61M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 64 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -0.004 p earnings per share for the quarter, the consensus estimate of -0.004 p by 0 p.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -0.004 p in its last earnings report, expectations of -0.004 p. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―